Kidney cancer targeted drug Pezopanib needs to be taken for life if the body has not developed drug resistance, but it should be used strictly under the guidance of the doctor in conjunction with one’s own situation.
Pezopanib is a multi-target tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1, 2 and 3, platelet-derived growth factor (receptor) α and β, fibroblast growth factor receptor-1 and -3, cytokine receptor, interleukin-2 receptor-induced T-cell kinase, leukocyte-specific protein tyrosine kinase, and transmembrane glycoprotein receptor tyrosine kinase.
It is indicated for the first-line treatment of patients with advanced renal cell carcinoma and for the treatment of patients with advanced renal cell carcinoma who have received previous cytokine therapy.
However, in the process of drug use, long-term use of the body may produce drug resistance, once drug resistance, need to follow the doctor’s advice to adjust the drug.
Patients need to follow their doctor’s advice to take pezopanib as long as they can benefit from its use until there are new changes in the disease. You should follow the doctor’s instructions during the medication, have regular physical checkups, and use the medication wisely under the doctor’s guidance.
In addition, this medication is irritating to the gastrointestinal tract and the systemic exposure of pezopanib increases when taken with food; it is recommended that the medication be taken at least 1 hour before a meal or at least 2 hours after a meal.